For decades, the general consensus among neurologists and neuroscientists has been that ALS treatments would only be able to slow down or stop further progression of the disease. Function that had already been lost would probably not be recovered.
But now, evidence is emerging that not only is functional improvement possible, it’s happening for some people with SOD1-ALS who have been treated with Qalsody® (tofersen).
Qalsody is a genetically targeted treatment approved by the U.S. Food and Drug Administration (FDA) in 2023 specifically for people with ALS caused by a mutation in the SOD1 gene, also known as SOD1-ALS. The therapy is injected directly into the spinal canal to stop toxic SOD1 proteins from being made.